Q-Line BiotechNSE:QLINE -5.15%12 Pretax Margin % is 14.08% as of Mar. 2025, which is 6% below its 10-year median of 15.03. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Q-Line Biotech ranks better than 77.36% on this metric.
The historical rank and industry rank for Q-Line Biotech's Pretax Margin % or its related term are showing as below:
NSE:QLINE'
s Pretax Margin % Range Over the Past 10 Years
Min: 14.08 Med: 15.03 Max: 16.33
Current: 14.08
NSE:QLINE's Pretax Margin % is ranked better than 77.36% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs NSE:QLINE: 14.08
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Q-Line Biotech Pretax Margin % Related Terms
Q-Line Biotech Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Pretax Margin % Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Pretax Margin %
16.33
15.03
14.08
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Pretax Margin %
16.33
15.03
14.08
NSE:QLINE vs ABT, SYK, MDT: Pretax Margin % Comparison
For the Medical Devices subindustry, Q-Line Biotech's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech (NSE:QLINE) has a Pretax Margin % of 14.08% as of Mar. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Q-Line Biotech and its competitors. This is near median its historical median of 15.03. Over the past decade, Q-Line Biotech's Pretax Margin % has ranged from 14.08 to 16.33. According to the industry distribution chart, Q-Line Biotech ranks #185 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 22.6%.
Is Q-Line Biotech's Pretax Margin % too high?
Q-Line Biotech's current Pretax Margin % of 14.08% is near median its 10-year median of 15.03. Over the past 10 years, this metric has ranged from a low of 14.08 to a high of 16.33. The Medical Devices & Instruments industry median Pretax Margin % is 2.40. Q-Line Biotech's value of 14.08% is 486.7% above this industry median. Based on the distribution chart, Q-Line Biotech ranks #185 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Pretax Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #185 out of 817 companies for Pretax Margin %. This places Q-Line Biotech in the top 23% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 2.40. Q-Line Biotech's value of 14.08% is 486.7% above this benchmark. Historically, Q-Line Biotech's own Pretax Margin % has ranged from 14.08 to 16.33 over the past decade. While the company's 10-year median is 15.03 vs. the industry median of 2.40, Q-Line Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.40, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current Pretax Margin % of 14.08% is 486.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current Pretax Margin % is 14.08%, which is near median its own 10-year median of 15.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Pretax Margin % of 14.08%. The current Pretax Margin % is 14.08%, which is near median its 10-year median of 15.03 and 486.7% above the Medical Devices & Instruments industry median of 2.40. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Pretax Margin % is 14.08% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score
Get the complete analysis for NSE:QLINE
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 